Aller au contenu principal
Profil bibliographique

Erica A. Green

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

4Publications signalées
65Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Virus-based gene therapy researchViral Infectious Diseases and Gene Expression in InsectsCAR-T cell therapy researchViral Infections and Immunology Research

Les publications récentes

Accès ouvert 2025 article OpenAlex

Development of an HEK293 Suspension Cell Culture Medium, Transient Transfection Optimization Workflow, and Analytics for Batch rAAV Manufacturing

Erica A. Green, Qiang Fu, Nelson Ndhairo, Thomas M Leibiger et autres

Recombinant adeno associated virus (rAAV) vectors have become popular delivery vehicles for in vivo gene therapies, but demand for rAAVs continues to outpace supply. Platform processes for rAAV production are being developed by many manufacturers, and transient chemical transfection of human embryonic …

us (code pays fourni par la source)

7 citations Biotechnology and Bioengineering
Accès ouvert 2024 article OpenAlex

Biolayer interferometry for adeno-associated virus capsid titer measurement and applications to upstream and downstream process development

Thomas M Leibiger, Luke A. Remmler, Erica A. Green, Kelvin H. Lee

Faster and more accurate analytical methods are needed to support the advancement of recombinant adeno-associated virus (rAAV) production systems. Recently, biolayer interferometry (BLI) has been developed for high-throughput AAV capsid titer measurement by functionalizing the AAVX ligand onto biosensor probes (AAVX-BLI). In …

us (code pays fourni par la source)

9 citations Molecular Therapy — Methods & Clinical Development
Accès ouvert 2023 article OpenAlex

Design space determination to optimize DNA complexation and full capsid formation in transient rAAV manufacturing

Qiang Fu, Yong Suk Lee, Erica A. Green, Yongdan Wang et autres

Recombinant adeno-associated virus (rAAV) vectors are a promising platform for in vivo gene therapies. However, cost-effective, well-characterized processes necessary to manufacture rAAV therapeutics are challenging to develop without an understanding of how process parameters (PPs) affect rAAV product quality attributes (PQAs). In …

us (code pays fourni par la source)

22 citations Biotechnology and Bioengineering

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.